Piper Sandler Reaffirms “Neutral” Rating for Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper Sandler in a report released on Tuesday,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock, down from their prior price objective of $138.00. Piper Sandler’s price objective suggests a potential downside of […]
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper Sandler in a report released on Tuesday,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock, down from their prior price objective of $138.00. Piper Sandler’s price objective suggests a potential downside of […]
